Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Morabito

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
ESMO Open|July 16, 2025
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patientsE A Martino, G Caridà, D Lofaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2008
Bortezomib, doxorubicin and dexamethasone in advanced multiple myelomaA Palumbo, F Gay, S Bringhen, et al.
Pathologica|March 8, 2012
Primary synovial sarcoma of the kidney. A case report with pathologic appraisal investigation and literature reviewA Pitino, S Squillaci, C Spairani, et al.
British Journal of Cancer|June 28, 2002
CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALLG Cutrona, P Tasso, M Dono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapyF Ferrara, F Morabito, B Martino, et al.
Blood Cancer Journal|September 10, 2016
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcomeD Ronchetti, M Manzoni, L Agnelli, et al.
Leukemia|February 5, 2015
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive diseaseF R Mauro, S Chauvie, F Paoloni, et al.
Cell Death & Disease|November 30, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1N Amodio, M T Di Martino, U Foresta, et al.
Leukemia|November 14, 2013
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II TrialA Cortelezzi, M Sciumè, A M Liberati, et al.
Leukemia|January 6, 2017
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapyG Cutrona, S Matis, M Colombo, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
ESMO Open|July 16, 2025
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patientsE A Martino, G Caridà, D Lofaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2008
Bortezomib, doxorubicin and dexamethasone in advanced multiple myelomaA Palumbo, F Gay, S Bringhen, et al.
Pathologica|March 8, 2012
Primary synovial sarcoma of the kidney. A case report with pathologic appraisal investigation and literature reviewA Pitino, S Squillaci, C Spairani, et al.
British Journal of Cancer|June 28, 2002
CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALLG Cutrona, P Tasso, M Dono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapyF Ferrara, F Morabito, B Martino, et al.
Blood Cancer Journal|September 10, 2016
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcomeD Ronchetti, M Manzoni, L Agnelli, et al.
Leukemia|February 5, 2015
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive diseaseF R Mauro, S Chauvie, F Paoloni, et al.
Cell Death & Disease|November 30, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1N Amodio, M T Di Martino, U Foresta, et al.
Leukemia|November 14, 2013
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II TrialA Cortelezzi, M Sciumè, A M Liberati, et al.
Leukemia|January 6, 2017
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapyG Cutrona, S Matis, M Colombo, et al.
Pageof 14